Last Update 24 Jun 26
HAE: Vascular Closure Optimism Will Face Ongoing Execution And Reporting Restructure Risk
Haemonetics enters this narrative update with a higher Street price target range, highlighted by Citi lifting its target to $70 from $64 and BofA raising its target to $80 from $72. Analysts reference updated medical technology models, a view that vascular closure may have turned a corner, and what they see as conservative guidance with potential upside across all three segments.
Analyst Commentary
Recent research on Haemonetics shows a split view, with some large firms highlighting potential upside while others remain more cautious. The differing opinions give you a clearer sense of where expectations may be stretched and where execution risk could matter most for the stock.
Citi raised its price target on Haemonetics to US$70 from US$64 and kept a Neutral stance after updating its medical technology models following Q1 results. The firm commented that fundamentals across the sector remain solid, which frames Haemonetics within a broader group view rather than as an outlier.
BofA took a more constructive stance, upgrading Haemonetics to Buy from Neutral and lifting its target to US$80 from US$72. The analyst pointed to a view that vascular closure has turned a corner and that plasma related upside appears more durable. They also viewed the company’s initial guidance across all three segments as cautious, with room for upside as the year progresses.
At the same time, several Bearish analysts have trimmed their targets on Haemonetics in recent months. Firms including JPMorgan, BTIG, Mizuho, Barrington, Baird and Citi have all reduced their stated targets by mid single to low teens dollar amounts, signaling that not everyone shares the more optimistic view implied by the latest raises.
Bearish Takeaways
- Bearish analysts cutting price targets by US$4 to US$12 suggest concern that prior expectations for Haemonetics may have been too high relative to current execution and visibility.
- Multiple target reductions clustered over a short period point to ongoing questions around the company’s growth trajectory, even as some bulls highlight potential upside in vascular closure and plasma.
- Lowered targets from larger firms such as JPMorgan can reflect caution on valuation, with some Bearish analysts appearing reluctant to underwrite more aggressive scenarios until guidance and results align more consistently.
- The mix of target increases and decreases underscores a wide range of views on Haemonetics, which can translate into choppier trading if the company does not clearly deliver on its guidance and segment level objectives.
What’s in the News for Haemonetics
- Haemonetics plans to revise its financial reporting structure from the first quarter of fiscal 2027, consolidating its Plasma and Blood Center units into a single Apheresis segment and renaming the Hospital segment to MedSurg, to align external reporting with how management runs the business. Source: company announcement.
- The company highlights its Apheresis segment as having around 80% market share through plasma collection systems and software contracts, reflecting the current positioning of this part of Haemonetics’ portfolio. Source: company announcement.
- Recent commentary in the same announcement describes Haemonetics as undervalued and references expectations for double digit organic growth, margin improvement and earnings quality changes tied to product innovation and adoption. This provides context for how some analysts frame the stock. Source: company announcement.
- Haemonetics received U.S. Food and Drug Administration approval to expand labeling for the VASCADE MVP XL venous vascular closure system to include larger procedural sheaths used in pulsed field ablation and left atrial appendage closure for atrial fibrillation treatment. The approval was supported by the AMBULATE EXPAND trial with 77 patients and 0% major and minor access site closure related complications. Source: FDA related company news.
- The VASCADE MVP XL system is now described as the only extravascular venous closure system clinically proven in electrophysiology procedures using up to 17F outer diameter procedural sheaths. It sits alongside the VASCADE and VASCADE MVP products in Haemonetics’ broader vascular closure portfolio. Source: FDA related company news.
Valuation Changes for Haemonetics
- Fair Value: Modelled fair value for Haemonetics remains unchanged at $62.0, indicating no revision to the central valuation output.
- Discount Rate: The discount rate has fallen slightly from 8.20% to 8.18%, a modest adjustment to the risk level applied in the valuation model.
- Revenue Growth: Assumed revenue growth has risen slightly from 4.89% to 4.97%, reflecting a small upward tweak to projected top line expansion in the Haemonetics model.
- Net Profit Margin: Assumed profit margin has edged down from 16.54% to 16.36%, suggesting a minor reduction in expected profitability levels.
- Future P/E: The future P/E multiple has risen slightly from 11.72x to 11.81x, implying a small change in how the model values Haemonetics earnings relative to price.
Key Takeaways
- Advances in bloodless surgery and intensifying competition could limit revenue growth and margin improvement in key segments if operational risks are not addressed.
- Exposure to reimbursement pressures, regulatory changes, and supply chain challenges may constrain earnings growth and cash flow sustainability despite strong innovation and partnerships.
- Heavy reliance on core U.S. markets and short-term gains exposes Haemonetics to competitive, regulatory, and cyclical risks that threaten long-term growth and profitability.
Catalysts
About Haemonetics- A medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
- While Haemonetics benefits from a global demographic tailwind fueled by an aging population and rising chronic diseases-which should ensure longer-term demand for plasma and transfusion products-there is a risk that continued medical advances in bloodless surgery and improved surgical techniques could eventually plateau demand, limiting topline revenue growth over time.
- Although strong innovation in plasma collection platforms and software adoption (especially NexSys and NexLynk) are driving share gains, operational execution risk remains in Vascular Closure and Interventional Technologies, where recent underperformance, increasing competition, and complex customer dynamics could stall expected margin expansion and subdue net margin improvement if not promptly addressed.
- While the company's increasing strategic partnerships and long-term contracts in plasma software promise recurring revenue and improved earnings visibility, reimbursement pressures from government and private payors globally could weigh on gross margins and threaten sustainable EPS growth.
- Even with firm momentum in hemostasis management and TEG 6S adoption, the hospital portfolio is concentrated in the U.S., heightening exposure to potential U.S. healthcare cost containment and regulatory policy changes, which could limit the pace of market expansion and dampen revenue growth if adverse conditions arise.
- Despite long-term growth opportunities in emerging markets driven by improved healthcare access, supply chain fragility, raw material shortages, and higher regulatory hurdles could result in intermittent disruptions and elevated operating expenses, which may constrain operating income growth and pressure long-term cash flow conversion.
Haemonetics Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Haemonetics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Haemonetics's revenue will grow by 5.0% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 7.3% today to 16.4% in 3 years time.
- The bearish analysts expect earnings to reach $252.5 million (and earnings per share of $5.62) by about June 2029, up from $97.3 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 11.9x on those 2029 earnings, down from 34.0x today. This future PE is lower than the current PE for the US Medical Equipment industry at 25.0x.
- The bearish analysts expect the number of shares outstanding to decline by 5.67% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.18%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Haemonetics' concentration of revenue and growth in three core products, with roughly 80% of revenue generated in the U.S., exposes the company to geographic and product-specific risks; shifts in U.S. healthcare policy or market saturation could limit revenue growth and compress margins over the longer term.
- The company acknowledges increased competition in its Vascular Closure and Interventional Technologies segments, including from low-cost competitors, with recent below-market growth in electrophysiology procedures; if Haemonetics fails to regain competitiveness, this could erode market share, reduce pricing power, and pressure segment revenues and margins.
- Plasma business momentum has been driven in part by one-time software licensing revenue and share gains, while underlying plasma collection volumes in the U.S. were described as flat and macrocyclical; overreliance on near-term pricing and share wins, rather than secular collection growth, could result in slower sustainable revenue expansion if volumes do not recover as projected.
- Investments in expanding salesforce capabilities, restructuring commercial teams, and ongoing R&D are required to address execution gaps and reignite underperforming business lines, but these add to operating expenses and could negatively impact net earnings growth if improvements do not materialize as expected.
- Long-term risks are highlighted by the cyclical nature of plasma collection, heightened productivity among customers reducing total collection needs, and persistent pressure from healthcare consolidation and cost containment, any of which could limit Haemonetics' pricing power, slow top-line growth, and compress operating margins in future years.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Haemonetics is $62.0, which represents up to two standard deviations below the consensus price target of $85.2. This valuation is based on what can be assumed as the expectations of Haemonetics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $104.0, and the most bearish reporting a price target of just $62.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.5 billion, earnings will come to $252.5 million, and it would be trading on a PE ratio of 11.9x, assuming you use a discount rate of 8.2%.
- Given the current share price of $72.78, the analyst price target of $62.0 is 17.4% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Haemonetics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
